New targeted therapy hopes to shrink Hard-to-Treat cancers
Disease control
Recruiting now
This study tests a new drug called TSN1611 in people with advanced solid tumors that have a specific gene change called KRAS G12D. The study has two parts: first, finding the safest dose, and then seeing how well it shrinks tumors. About 440 adults with various advanced cancers w…
Phase: PHASE1, PHASE2 • Sponsor: Tyligand Pharmaceuticals (Suzhou) Limited • Aim: Disease control
Last updated May 14, 2026 12:05 UTC